Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3827494 | 0.85 | CTSK (0.38) | CTSKCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL13567949 | 0.84 | CTSK (0.45) | CTSKCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL3837383 | 0.77 | ALDH1A1 (0.40) | CHRM2CTSB | |
| SCHEMBL17802003 | 0.76 | BLM (0.39) | CTSKCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL3827851 | 0.76 | CTSK (0.39) | CTSKCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL24596804 | 0.74 | CTSK (0.41) | CTSKCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL30784696 | 0.74 | CTSK (0.35) | CTSKCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL3833967 | 0.73 | ALDH1A1 (0.37) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL21224845 | 0.72 | CHRNB2 (0.38) | CTSKCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL28769254 | 0.72 | CTSK (0.35) | CTSKCHRM2CHRM4CHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312310-A1 | Imidazothiazole derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| EP-2103619-A1 | IMIDAZOTHIAZOLE DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312310-A1 | Imidazothiazole derivatives | TP53, MDM2, TP53BP1 | CTSK 3724/4885CHRM2 3444/4885CHRM4 4178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.